U.S. Markets closed

Why Acadia Pharmaceuticals Stock Is Rocketing Today

·2 min read
Why Acadia Pharmaceuticals Stock Is Rocketing Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by as much as 19.2% in premarket trading Tuesday morning. The biotech's stock is taking flight today in response to a positive clinical readout for its experimental Rett syndrome drug known as trofinetide. Rett syndrome is a rare genetic disorder characterized by the progressive degeneration of motor and speech skills.